Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis

An overview of a Cochrane systematic review that compares the use of Fixed-Dose Combinations (FDCs) of drugs versus single-drug formulations for treating new cases of pulmonary tuberculosis (TB). The review, published in 2016 by the Cochrane Infectious Diseases Group, analyzes data from 13 randomized controlled trials (RCTs) involving over 5,800 participants to assess the efficacy, safety, and acceptability of FDCs. The results suggest little or no difference between FDCs and single-drug formulations for most outcomes, including treatment failure and death, although relapse may be slightly more frequent with FDCs, despite the World Health Organization recommending FDCs to improve patient adherence. The document includes detailed methodology, analysis comparisons, and risk of bias assessments for the included studies.You can listen and download our episodes for free on more than 10 different platforms:https://linktr.ee/pharmacy_simpleProduced by:https://www.podcaistudio.com/